Results 191 to 200 of about 4,211,479 (248)
Developing a standard definition for sequences of concern. [PDF]
Front Bioeng BiotechnolAlexanian T, Beal J, Bartling C, Berlips J, Carr PA, Clore A, Cozzarini H, Diggans J, El Moubayed Y, Esvelt K, Flyangolts K, Foner L, Fullerton PA, Gemler BT, Jagla CAD, Lababidi R, Mitchell T, Murphy ST, Parker MT, Roehner N, Rusch A, Talley K, Timmerman T, Wheeler NE. +23 moreeuropepmc +1 more sourceCCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3
Molecular Oncology, EarlyView.PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets +12 morewiley +1 more sourceOncologic Safety of Omitting Mediastinal Lymph Node Dissection in Segmentectomy for Ground-Glass Opacity-Dominant Lung Cancer: A Supplementary Analysis of JCOG1211. [PDF]
Eur J Cardiothorac SurgOnodera K, Aokage K, Saji H, Wakabayashi M, Endo M, Tsutani Y, Nakagawa K, Shimada Y, Isaka T, Isaka M, Nakajima R, Hattori A, Maniwa T, Mimae T, Miyoshi T, Yoshioka H, Yotsukura M, Mitome N, Uozumi T, Fukuda H, Watanabe SI, Suzuki K. +21 moreeuropepmc +1 more sourceKDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan +16 morewiley +1 more sourceDiphtheria outbreak, Northern Territory of Australia, 2025 to 2026. [PDF]
Euro SurveillDraper AD, Sistrom M, McMahon K, Duguid R, Chen J, Cramp G, Cherian T, Miri Nargesi M, Sutandar D, Freeman K, Lomas K, Tolotta T, Gunn JC, Boyd R, Hennessy J, Creeper T, Harbidge J, Sarmiento F, Curr R, Yan J, Francis JR, Baird R, Stratton H, Davies J, Marshall CS, Janson S, Moore N, Wardell R, Athan E, Drewett G, Moore L, Layton E, Susil Kumar U, Webby R, Yadav A, Krause VL, Ravindran B, Meumann EM. +37 moreeuropepmc +1 more sourceTranscriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients
Molecular Oncology, EarlyView.RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel +14 morewiley +1 more sourceReal-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study. [PDF]
Curr OncolSeyyar M, Kalem A, Sali M, Karabuğa B, Sahin TK, Dişli AK, Türkel A, Karadurmuş B, Şahin Hafızoğlu E, Avcı N, Bilgetekin I, Köse Baytemur N, Uguztemur E, Oflazoğlu U, Gür HB, Hacıbekiroğlu İ, Akkuş AF, Topaloğlu S, Bayramgil A, Dülgar Kaya Ö, Yazıcı M, Şakalar T, Akay S, Majidova N, Guliyev M, Alan Ö, Gülcü S, Eren T, İmamoğlu Gİ, Güren AK, Köstek O, Ünlü A, Ozturk B, Aydın E, Safarov S, Doğan B, Tükenmez MA, Demir T, Şahin E, Erdemoğlu E, Keskin Uzundere F, Bütün O, Karabulut B, Uzun M, Baydaş T, Karaman E, Arak H, Ekinci F, Aykan MB, Ertürk İ, Guven DC, Deligönül A, Karaçin C, Ateş Ö, İnanç M, Yeşil H, Aksoy S, Köşeci T, Ökten İN, Yıldırım HÇ, Çabuk D. +60 moreeuropepmc +1 more sourceLongitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel
Molecular Oncology, EarlyView.Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay +15 morewiley +1 more sourceReal-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort. [PDF]
OncologistMascaró-Baselga P, Rodellar Sanz JM, Nunes da Silva T, Hernando J, García-Álvarez A, González Merino C, Molina-Cerrillo J, Fernandez-Pombo A, Iglesias-Alvarez G, Ceballos Lenza I, Plana Serrahima M, Bella Cueto MR, Isidro ML, Martinez Trufero J, Marquina G, Martinez N, Crespo G, Jimeno R, Lorenzo I, Ayala de Miguel P, Alcazar V, Martínez-Badal S, Capdevila J, Alonso-Gordoa T. +23 moreeuropepmc +1 more source
